Unknown KOIN.com

Unknown KOIN.com is a news website that features various anchors and reporters. The team consists of Jeff Gianola, Jennifer Hoff, Ken Boddie, Jenny Hansson, Dan Tilkin, Trevor Ault, Chris Holmstrom, Anna Canzano, Eileen Park, Carly Kennelly, Joseph Dames, Claire Anderson , Lisa Balick , Tim Becker , Adam Bjaranson , Jennifer Dowling , Amy Frazier , Kohr Harlan , AJ McCord and Cole Miller. They cover a wide range of topics and provide local news to the community. Some of the reporters have backgrounds in journalism, while others have degrees in related fields. The team is experienced and has been reporting news for many years.

Biography:  https://www.koin.com/about-us/meet-the-koin-6-news-team/

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

GLP-1: A Game Changer in Obesity Therapy and Beyond

GLP-1: A Game Changer in Obesity Therapy and Beyond

Broke On: Saturday, 15 June 2024 GLP-1, a satiety hormone discovered in groundbreaking research, shows promise for obesity therapy and type 2 diabetes remission. GLP-1 drugs have led to weight loss and improved cardiovascular health, despite some side effects. Ongoing research aims to enhance their efficacy and expand their applications beyond obesity.